The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
Official Title: The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China
Study ID: NCT02980536
Brief Summary: The purpose of this study is to evaluate the mutation pattern of epidermal growth factor receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient with liquid biopsy.
Detailed Description: In the study, 200 advanced NSCLC patients will be recruited. All the patients will receive biopsy genotype assay and Circulating Single-Molecule Amplification and Resequencing Technology (cSMART) liquid biopsy. those patients who carry EGFR activating mutation and other TKI targeted activating mutation will receive TKI treatment. During the TKI treatment, every patients will take liquid biopsy assay to monitor the mutation status. the study will be ended when all the patients had a progressive disease (PD) in their targeted lesion
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Baogang Hospital, Baotou, Inner Mongolia, China
Baotou Cancer Hospital, Baotou, Inner Mongolia, China
Northern Hospital Baotou, Baotou, Inner Mongolia, China
Baotou Centry Hospital, Baotou, Inner Mongolia, China
Bayan Nur Hospital, Bayan Nur, Inner Mongolia, China
The Inner Mongolia Autonomous Region Cancer Hospital, Hohhot, Inner Mongolia, China
The Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia, China
The First Affiliated Hospital of Inner Monglia Medical University, Hohhot, Inner Mongolia, China
Dalad Banner People's Hospital, Ordos, Inner Mongolia, China
Name: Shun Lu, MD/PhD
Affiliation: Shanghai Chest Hospital
Role: STUDY_CHAIR